Key facts
- This page summarizes Lynn Kirkpatrick's Form 4 filing for Ensysce Biosciences, Inc. (ENSC).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 May 2022, 14:05.
Lynn Kirkpatrick - 25 May 2022 Form 4 Insider Report for Ensysce Biosciences, Inc. (ENSC)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ENSC
- Reported as of
- 25 May 2022
- Net transaction value
- +$48,298
- SEC form
- 4
- Accepted by SEC
- 27 May 2022, 14:05:01 UTC
- Prior SEC filing
- 24 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lynn Kirkpatrick
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Lynn Kirkpatrick filed Form 4 for Ensysce Biosciences, Inc. (ENSC) on 27 May 2022.
Change
- Previous filing in this sequence was filed on 24 Feb 2022.
- Current net transaction value: +$48,298.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ENSC
transaction
Common Stock
Purchase
- Transaction value
- $34,083
- Shares
- +70,000
- Change %
- +25%
- Price
- $0.4869
- Shares after
- 354,851
- Date
- 25 May 2022
- Ownership
- Direct
ENSC
transaction
Common Stock
Purchase
- Transaction value
- $14,216
- Shares
- +27,000
- Change %
- +7.6%
- Price
- $0.5265
- Shares after
- 381,851
- Date
- 26 May 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ENSC
transaction
Derivative
Stock Option
Award
- Transaction value
- Shares
- +200,000
- Change %
- +8.6%
- Price
- Shares after
- 2,516,939
- Date
- 17 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $1.40
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9.